HK Stock Market Move | BeOne Medicines Ltd. (06160) increased by more than 4% with an additional investment of 300 million US dollars to expand its production layout in the United States.

BeOne Medicines Ltd. (06160) rose more than 4%, up 4.02% at the time of writing, to 202.6 Hong Kong dollars, with a turnover of 170 million Hong Kong dollars. On the news front, on July 23, BeOne Medicines Ltd. announced an additional investment of $300 million to expand its flagship production base and clinical R&D center in the Princeton West Innovation Park in New Jersey, USA, adding small molecule drug production capacity. The additional capacity will support the company's various blood cancer projects, as well as pipeline projects for breast cancer, gynecological tumors, lung cancer, liver cancer, gastrointestinal tumors, and other types of tumors. Securities recently pointed out that BeOne Medicines Ltd. has become a lightweight MNC with stable hematopoietic capacity, global commercial execution capabilities, and systematic research and development efficiency. Its top clinical operations and research and development model in the industry is an underestimated invisible moat beyond pipeline value. The combined development of BeOne Medicines Ltd.'s pipeline makes the value of its products greater than the simple sum of product valuation.